Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Oct 5:10:451.
doi: 10.3389/fnins.2016.00451. eCollection 2016.

Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases

Samuele Maramai  1 , Sandra Gemma  1 , Simone Brogi  1 , Giuseppe Campiani  1 , Stefania Butini  1 , Holger Stark  2 , Margherita Brindisi  1
Affiliations
Review

Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases

Samuele Maramai et al. Front Neurosci. .

Abstract

D3 receptors represent a major focus of current drug design and development of therapeutics for dopamine-related pathological states. Their close homology with the D2 receptor subtype makes the development of D3 selective antagonists a challenging task. In this review, we explore the relevance and therapeutic utility of D3 antagonists or partial agonists endowed with multireceptor affinity profile in the field of central nervous system disorders such as schizophrenia and drug abuse. In fact, the peculiar distribution and low brain abundance of D3 receptors make them a valuable target for the development of drugs devoid of motor side effects classically elicited by D2 antagonists. Recent research efforts were devoted to the conception of chemical templates possibly endowed with a multi-target profile, especially with regards to other G-protein-coupled receptors (GPCRs). A comprehensive overview of the recent literature in the field is herein provided. In particular, the evolution of the chemical templates has been tracked, according to the growing advancements in both the structural information and the refinement of the key pharmacophoric elements. The receptor/multireceptor affinity and functional profiles for the examined compounds have been covered, together with their most significant pharmacological applications.

Keywords: GPCR; dopamine; drug optimization; multi-targeting approach; receptor antagonists; selectivity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Alignment between D1 receptor (as an example of D1-like family) and D3 receptor (as an example of D2-like family) as found by PRALINE (http://www.ibi.vu.nl/programs/pralinewww/), non-conserved residues are highlighted by dark blue background. (B) Snake plot representation of the above-mentioned receptors with the non-conserved residues in green for D1 receptor and in orange for D3 receptor. Plots were generated by means of GPCRdb web-server (http://gpcrdb.org/).
Figure 2
Figure 2
Pharmacophore model for D3 selective ligands.
Figure 3
Figure 3
Early identified D3 selective ligands.
Figure 4
Figure 4
Arylpiperazine-based derivatives 5-10.
Figure 5
Figure 5
Arylpiperazine-based derivatives 11-15.
Figure 6
Figure 6
Pyrimidinylpiperazine-based compounds 16–19.
Figure 7
Figure 7
Deconstruction studies performed on D3 receptor ligands 6a and 20.
Figure 8
Figure 8
Schematic representation of the flexible arylpiperazinecarboxamides binding the OBS and SBP of the D3 receptor.
Figure 9
Figure 9
Arylpiperazine-based D3 “dimeric” and bitopic ligands 28 and 29.
Figure 10
Figure 10
Tranylcypromine (30) and Tranylcypromine-based analog 31.
Figure 11
Figure 11
Compounds 32 and 33 and structurally related triazole-based D3 antagonists 34–36.
Figure 12
Figure 12
Representation of the novel pharmacophoric model proposed by Micheli et al. (Bonanomi et al., ; Micheli et al., 2010b), with compound 35 and its features.
Figure 13
Figure 13
Morpholino/triazole analogs 37a–c.
Figure 14
Figure 14
General structure of octahydropyrrolo[2,3-b]pyrrole-based D3 antagonists 38 and 39.
See this image and copyright information in PMC

References

    1. Agai-Csongor E., Domány G., Nogradi K., Galambos J., Vago I., Keseru G. M., et al. (2012). Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors. Bioorg. Med. Chem. Lett. 22, 3437–3440. 10.1016/j.bmcl.2012.03.104 - DOI - PubMed
    1. Agnati L. F., Guidolin D., Cervetto C., Borroto-Escuela D. O., Fuxe K. (2016). Role of iso-receptors in receptor-receptor interactions with a focus on dopamine iso-receptor complexes. Rev. Neurosci. 27, 1–25. 10.1515/revneuro-2015-0024 - DOI - PubMed
    1. Ananthan S., Saini S. K., Zhou G., Hobrath J. V., Padmalayam I., Zhai L., et al. (2014). Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity. J. Med. Chem. 57, 7042–7060. 10.1021/jm500801r - DOI - PMC - PubMed
    1. Aragona B. J., Day J. J., Roitman M. F., Cleaveland N. A., Wightman R. M., Carelli R. M. (2009). Regional specificity in the real-time development of phasic dopamine transmission patterns during acquisition of a cue-cocaine association in rats. Eur. J. Neurosci. 30, 1889–1899. 10.1111/j.1460-9568.2009.07027.x - DOI - PMC - PubMed
    1. Beaulieu J. M., Gainetdinov R. R. (2011). The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 63, 182–217. 10.1124/pr.110.002642 - DOI - PubMed